Published in Vaccine Weekly, October 20th, 2004
Together with two papers validating cancer antigens published by independent groups, Cerus now has mounting evidence supporting the intensified development of its cancer immunotherapy technology. The most recent paper describes studies in which experimental vaccines based on a proprietary attenuated listeria strain were engineered to express tumor antigens.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.